

Daryl Geers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9778699/publications.pdf>

Version: 2024-02-01

9
papers

1,151
citations

1163117

8
h-index

1474206

9
g-index

13
all docs

13
docs citations

13
times ranked

1939
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	11.9	455
2	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	11.9	337
3	The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. <i>Transplantation</i> , 2022, 106, 821-834.	1.0	127
4	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COVS.S Priming. <i>New England Journal of Medicine</i> , 2022, 386, 951-963.	27.0	102
5	Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1949-1957.	2.9	39
6	Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. <i>Clinical Infectious Diseases</i> , 2023, 76, e188-e199.	5.8	24
7	Difference in sensitivity between SARS-CoV-2-specific T cell assays in patients with underlying conditions. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
8	Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern. <i>MBio</i> , 2022, 13, .	4.1	9
9	Durability of Immune Responses After Boosting in Ad26.COVS.S-Primed Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2023, 76, e533-e536.	5.8	7